Showing results (41-50 of 54) with videos related to
Sort By:
Pageof 6
Journal for Immunotherapy of Cancer|January 2, 2024
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancerKurt A Jenkins, Miso Park, Magali Pederzoli-Ribeil, et al.Journal of Medicinal Chemistry|May 27, 2005
Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitorVenkat R Macherla, Scott S Mitchell, Rama Rao Manam, et al.Cancer Cell|December 5, 2025
Tumor-initiating stem cells fine-tune the plasticity of neutrophils to sculpt a protective nicheWeijie Guo, Jingyun Luan, Xuejie Huang, et al.Ebiomedicine|October 30, 2016
Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3+ T-regulatory Cell Function and Promotes Antitumor ImmunityLiqing Wang, Suresh Kumar, Satinder Dahiya, et al.Chemistry & Biology|November 29, 2011
Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymesMikael Altun, Holger B Kramer, Lianne I Willems, et al.Journal of Medicinal Chemistry|December 22, 2011
Synthesis and structure-activity relationship study of antimicrotubule agents phenylahistin derivatives with a didehydropiperazine-2,5-dione structureYuri Yamazaki, Koji Tanaka, Benjamin Nicholson, et al.Cancer Cell|September 15, 2012
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistanceDharminder Chauhan, Ze Tian, Benjamin Nicholson, et al.Nature Communications|July 5, 2020
Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug targetJoseph W Franses, Julia Philipp, Pavlos Missios, et al.Blood Cancer Discovery|April 11, 2022
Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative NeoplasmsJuan Ibarra, Yassmin A Elbanna, Katarzyna Kurylowicz, et al.Molecular Cancer Therapeutics|November 29, 2023
XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical StudiesEkta Patel, Natalia V Malkova, David Crowe, et al.Pageof 6